|本期目录/Table of Contents|

[1]许星星,罗芸,王贤军,等.国内外艰难梭菌感染现状分析[J].传染病信息,2018,02:175-180.
 XU Xing-xing,LUO Yun,WANG Xian-jun,et al.Analysis of present situation of Clostridium difficile infections in the world[J].Infectious Disease Information,2018,02:175-180.
点击复制

国内外艰难梭菌感染现状分析(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年02期
页码:
175-180
栏目:
综述
出版日期:
2018-03-20

文章信息/Info

Title:
Analysis of present situation of Clostridium difficile infections in the world
作者:
许星星罗芸王贤军金大智
310006,浙江中医药大学附属杭州市第一医院检验科(许星星、王贤军);310051 杭州,浙江省疾病预防控制中心微生物 检验所(许星星、罗芸、金大智)
Author(s):
XU Xing-xing LUO Yun WANG Xian-jun JIN Da-zhi*
Department of Laboratory Medicine, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, 310006, China Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
关键词:
艰难梭菌感染危险因素临床表现现状
Keywords:
Clostridium difficile infection risk factors clinical manifestations current situation
分类号:
R378
DOI:
10.3969/j.issn.1007-8134.2018.02.020
文献标识码:
A
摘要:
艰难梭菌是一种革兰阳性厌氧芽孢杆菌,也是抗生素相关性腹泻的主要病原菌之一。近年来,由于高毒力菌 株核糖体027 型的出现,导致艰难梭菌感染在世界范围内的暴发和流行。目前,艰难梭菌分子流行病学研究进展迅速,不同 地区的艰难梭菌具有不同的感染特点。北美和欧洲等发达国家的流行病学特征已经比较清楚,该菌在中国的研究起步较晚, 但近几年的研究也初步呈现出中国艰难梭菌感染现状和分子特征。本文从艰难梭菌感染的临床表现、危险因素、国内外感染 现状等角度进行综述,为后续进一步推进中国艰难梭菌感染防控及分子流行病学研究提供数据参考。
Abstract:
Clostridium difficile (C. difficile) is a Gram-positive anaerobic bacillus and also one of microbial pathogens causing antibiotic-associated diarrhea. In recent years, the emergence of hyper-virulent ribotype 027 strains results in the worldwide epidemics of C. difficile infection (CDI). At present, numerous researches on C. difficile molecular epidemiology in the world have been conducted rapidly, and the molecular epidemiological characteristics vary in different regions. The characteristics of molecular epidemiology in developed countries including North America and Europe are relatively clear. Although the researches on CDI in China have lagged, the latest studies have showed molecular characteristics and current situation of CDI in China. This paper aims to review the latest advances of clinical manifestations, risk factors and current situation of CDI, in order to provide data evidence for further prevention and control of CDI, as well as C. difficile molecular epidemiology study in China.

参考文献/References

[1] Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever[J]. N Engl J Med, 2008, 359(18):1932-1940.
[2] He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile[J]. Nat Genet, 2013, 45(1):109-113.
[3] Wang R, Chen HX, Song LJ, et al. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from the Chinese People's Liberation Army General Hospital in China[J]. Int J Infect Dis, 2018, 67:86-91.
[4] Peng Z, Jin D, Kim HB, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing[J]. J Clin Microbiol, 2017, 55(7):1998- 2008.
[5] Brito GA, Sullivan GW, Ciesla WP, et al. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function[J]. J Infect Dis, 2002, 185(9):1297-1306.
[6] Kazanowski M, Smolarek S, Kinnarney F, et al. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review[J]. Tech Coloproctol, 2014, 18(3):223-232.
[7] Gerding DN, Johnson S, Rupnik M, et al. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance[J]. Gut Microbes, 2014, 5(1):15-27.
[8] Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) [J]. Infect Control Hosp Epidemiol, 2010, 31(5):431-455.
[9] 曲芬,汤一苇. 艰难梭菌感染的流行状况及诊治进展[J]. 传 染病信息, 2010,23(1):8-10.
[10] Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection[J]. Clin Infect Dis, 2011, 52(12):1451-1457.
[11] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4):478-498; quiz 499.
[12] Jin D, Luo Y, Huang C, et al. Molecular epidemiology of Clostridium difficile infection in hospitalized patients in eastern China[J]. J Clin Microbiol, 2017, 55(3):801-810.
[13] Steele SR, McCormick J, Melton GB, et al. Practice parameters for the management of Clostridium difficile infection[J]. Dis Colon Rectum, 2015, 58(1):10-24.
[14] Hawkey PM, Marriott C, Liu WE, et al. Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia?[J]. J Clin Microbiol, 2013, 51(10):3308-3313.
[15] Vindigni SM, Surawicz CM. C. difficile infection: changing epidemiology and management paradigms[J]. Clin Transl Gastroenterol, 2015, 6:e99.
[16] Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea [J]. Aliment Pharmacol Ther, 2006, 24(4):613-619.
[17] Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections[J]. Clin Microbiol Rev, 2010, 23(3):529-549.
[18] Lagier JC, Dubourg G, Cassir N, et al. Clostridium difficile 027 emerging outbreak in Marseille, France[J]. Infect Control Hosp Epidemiol, 2013, 34(12):1339-1341.
[19] Orsi GB, Conti C, Mancini C, et al. Clostridium difficile 027 increasing detection in a teaching hospital in Rome, Italy[J]. Infection, 2014, 42(5):941-942.
[20] Arvand M, Vollandt D, Bettge-Weller G, et al. Increased incidence of Clostridium difficile PCR ribotype 027 in Hesse, Germany, 2011 to 2013[J]. Euro Surveill, 2014, 19(10).
[21] Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID) [J]. Lancet Infect Dis, 2014, 14(12):1208-1219.
[22] Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey[J]. Lancet, 2011, 377(9759):63-73.
[23] Davies KA, Ashwin H, Longshaw CM, et al. Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013[J]. Euro Surveill, 2016, 21(29).
[24] Wilcox MH, Shetty N, Fawley WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England[J]. Clin Infect Dis, 2012, 55(8):1056-1063.
[25] Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective[J]. J Infect, 2013, 66(2):115-128.
[26] Levy AR, Szabo SM, Lozano-Ortega G, et al. Incidence and costs of Clostridium difficile infections in Canada[J]. Open Forum Infect Dis, 2015, 2(3):ofv076.
[27] Reveles KR, Lee GC, Boyd NK, et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010[J]. Am J Infect Control, 2014, 42(10):1028- 1032.
[28] Feuerstadt P, Das R, Brandt LJ. The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008[J]. Am J Gastroenterol, 2014, 109(8):1265-1276.
[29] Lessa FC, Winston LG, McDonald LC. Burden of Clostridium difficile infection in the United States[J]. N Engl J Med, 2015, 372(24):2369-2370.
[30] Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study[J]. Ann Intern Med, 2017, 167(3):152- 158.
[31] Nanwa N, Kendzerska T, Krahn M, et al. The economic impact of Clostridium difficile infection: a systematic review[J]. Am J Gastroenterol, 2015, 110(4):511-519.
[32] Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia[J]. Antimicrob Resist Infect Control, 2013, 2(1):21.
[33] Choi HY, Park SY, Kim YA, et al. The epidemiology and economic burden of Clostridium difficile infection in Korea[J]. Biomed Res Int, 2015, 2015:510386.
[34] Borren NZ, Ghadermarzi S, Hutfless S, et al. The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact[J]. PLoS One, 2017, 12(5):e0176797.
[35] Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections[J]. MMWR Morb Mortal Wkly Rep, 2012, 61(9):157-162.
[36] Cairns MD, Preston MD, Hall CL, et al. Comparative genome analysis and global phylogeny of the toxin variant Clostridium difficile PCR ribotype 017 reveals the evolution of two independent sublineages[J]. J Clin Microbiol, 2017, 55(3):865-876.
[37] Ho J, Dai RZW, Kwong TNY, et al. Disease burden of Clostridium difficile infections in adults, Hong Kong, China, 2006-2014[J]. Emerg Infect Dis, 2017, 23(10):1671-1679.
[38] Wong SH, Ip M, Hawkey PM, et al. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong[J]. J Infect, 2016, 73(2):115-122.
[39] Lee JC, Hung YP, Lin HJ, et al. Clostridium difficile infections in medical intensive care units of a medical center in southern Taiwan: variable seasonality and disease severity[J] PLoS One, 2016, 11(8):e0160760.
[40] Chung CH, Wu CJ, Lee HC, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis[J]. J Microbiol Immunol Infect, 2010, 43(2):119-125.
[41] Argamany JR, Aitken SL, Lee GC, et al. Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010[J]. Am J Infect Control, 2015, 43(5):435-440.
[42] Gilca R, Fortin E, Frenette C, et al. Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada[J]. Antimicrob Agents Chemother, 2012, 56(2):639-646.
[43] Hung YP, Huang IH, Lin HJ, et al. Predominance of Clostridium difficile ribotypes 017 and 078 among toxigenic clinical isolates in Southern Taiwan[J]. PLoS One, 2016, 11(11):e0166159.
[44] Tsai BY, Ko WC, Chen TH, et al. Zoonotic potential of the Clostridium difficile RT078 family in Taiwan[J]. Anaerobe, 2016, 41:125-130.
[45] Cheng JW, Xiao M, Kudinha T, et al. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from a university teaching hospital in China[J]. Front Microbiol, 2016, 7: 1621.
[46] Wang P, Zhou Y, Wang Z, et al. Identification of Clostridium difficile ribotype 027 for the first time in Mainland China[J]. Infect Control Hosp Epidemiol, 2014, 35(1):95-98.
[47] Huang H, Wu S, Chen R, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China[J]. Anaerobe, 2014, 30:65-69.
[48] King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations[J]. Future Microbiol, 2015, 10(1):1-4.
[49] Qin J, Dai Y, Ma X, et al. Nosocomial transmission of Clostridium difficile genotype st81 in a general teaching hospital in China traced by whole genome sequencing[J]. Sci Rep, 2017, 7(1): 9627.
[50] Hung YP, Lee JC, Lin HJ, et al. Clinical impact of Clostridium difficile colonization[J]. J Microbiol Immunol Infect, 2015, 48(3):241-248.
[51] Zacharioudakis IM, Zervou FN, Pliakos EE, et al. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2015, 110(3): 381-390.
[52] Ye GY, Li N, Chen YB, et al. Clostridium difficile carriage in healthy pregnant women in China[J]. Anaerobe, 2016, 37:54- 57.
[53] Zheng Y, Luo Y, Lv Y, et al. Clostridium difficile colonization in preoperative colorectal cancer patients[J]. Oncotarget, 2017, 8(7):11877-11886.

备注/Memo

备注/Memo:
[基金项目] 国家卫生计生委科学研究基金- 浙江省医药卫生重大科技计划(WKJ-ZJ-1507);浙江省重点研发计划(2015C03048); 国家自然科学基金(81471998);浙江省医药卫生科技计划项目- 重点学科带头人平台(2016DTB005)
[通信作者] 金大智,E-mail: dzjin@cdc.zj.cn
更新日期/Last Update: 2018-03-20